CRISPR Therapeutics AG (NASDAQ:CRSP) and Avid Bioservices Inc. (NASDAQ:CDMOP) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics AG | 59 | 0.00 | 34.37M | -0.46 | 0.00 |
| Avid Bioservices Inc. | 27 | 0.00 | 42.71M | -0.18 | 0.00 |
Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of CRISPR Therapeutics AG and Avid Bioservices Inc.
Profitability
Table 2 represents CRISPR Therapeutics AG (NASDAQ:CRSP) and Avid Bioservices Inc. (NASDAQ:CDMOP)’s return on assets, return on equity and net margins.
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics AG | 57,959,527.82% | -2.6% | -2% |
| Avid Bioservices Inc. | 160,082,458.77% | 0% | 0% |
Analyst Recommendations
The Ratings and Recommendations for CRISPR Therapeutics AG and Avid Bioservices Inc. are featured in the next table.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| CRISPR Therapeutics AG | 0 | 0 | 3 | 3.00 |
| Avid Bioservices Inc. | 0 | 0 | 0 | 0.00 |
CRISPR Therapeutics AG’s upside potential currently stands at 10.16% and an $72 consensus price target.
Institutional and Insider Ownership
CRISPR Therapeutics AG and Avid Bioservices Inc. has shares owned by institutional investors as follows: 46.8% and 0.72%. Insiders owned 0.4% of CRISPR Therapeutics AG shares. Competitively, insiders own roughly 7.06% of Avid Bioservices Inc.’s shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| CRISPR Therapeutics AG | 1% | 49.37% | 59.3% | 63.07% | 101.48% | 153.31% |
| Avid Bioservices Inc. | 0.24% | 0.8% | -2.15% | 2.74% | 2.85% | 6.44% |
For the past year CRISPR Therapeutics AG was more bullish than Avid Bioservices Inc.
Summary
On 6 of the 10 factors Avid Bioservices Inc. beats CRISPR Therapeutics AG.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
